Teva and Polpharma Biologics Announce Global Licensing Agreement for A Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
Latest news
Polpharma Biologics invests in the practical education of its employees in the field of biotechnology.
Polpharma Biologics participates in 24th BIO-Europe conference in Copenhagen (Denmark) where we present our fully int...
CPhI Worldwide is the biggest event with over 28 years’ experience of bringing the pharmaceutical world together.
Polpharma Biologics has inaugurated the first edition of BIO Academy (BIO Akademia), the largest practical education...
CRANBURY, N.J., March 27, 2018 (GLOBE NEWSWIRE) — Oncobiologics, Inc. (NASDAQ:ONS) today announced the appointment of...
Polpharma Career Lab – an internship programme designed for students and graduates in Biotechnology and related scien...
The Jury of the Golden Clips 2016 competition has awarded the golden statuette to the Polpharma Career Laboratory pro...